Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT02972151
Other study ID # 42501190
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received November 17, 2016
Last updated November 21, 2016
Start date November 2016
Est. completion date December 2018

Study information

Verified date October 2016
Source Shanghai University of Traditional Chinese Medicine
Contact lianwei xu, Doctor
Phone 64385700-3912
Email sherryxlw@hotmail.com
Is FDA regulated No
Health authority China: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The trial attempts to optimize, standardize and simplify the characteristic diagnosis and treatment program of the dominant diseases in our hospital-the sequelae of pelvic inflammatory disease, so as to make it suitable for clinical diagnosis and treatment in primary hospital.


Description:

Sequelae of pelvic inflammatory disease (SPID) is a common cause of chronic pelvic pain, ectopic pregnancy and infertility, which seriously affects the physical and mental health of the patients, quality of life and family happiness. Western medicine for pelvic inflammatory disease sequelae is still lack of effective treatment methods, traditional Chinese medicine treatment of this disease has a unique advantage, with broad prospects for development..Standardized diagnosis and treatment scheme of this project on the one hand, improve and optimize the sequelae of pelvic inflammatory disease, including according to the dialectical treatment of herbal medicine combined with TCM (traditional Chinese medicine enema, external application of Chinese medicine intervention treatment); on the other hand, to observe the clinical curative effect and adverse reaction of traditional Chinese medicine comprehensive treatment.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 175
Est. completion date December 2018
Est. primary completion date December 2018
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 60 Years
Eligibility Inclusion Criteria:

1. Patients with diagnostic criteria for the sequelae of pelvic inflammatory disease in Western medicine;

2. Patients conforming to the criteria of TCM syndrome differentiation;

3. Age 18--60 years old, married or sexual life;

4. In this study, the voluntary participation, and signed informed consent;

Exclusion Criteria:

1. Patients who do not meet the diagnostic criteria of Western medicine and traditional Chinese medicine dialectical typing standard;

2. Persons with acute pelvic inflammatory disease;

3. Related symptoms caused by diseasesGynecological tumor,specific vaginitis, acute cervicitis, pelvic congestion syndrome, endometriosis, adenomyosis, pelvic tuberculosis etc.

4. Pregnant and lactating women;

5. With severe primary disease, such as liver, kidney, heart, brain and hematopoietic system;

6. Allergic to a variety of drugs or known to be allergic to the composition of the use of traditional Chinese Medicine;

7. Patients taking part in other clinical trials;

8. Suspect or do have a history of alcohol, drug abuse or according to the judgment of the researcher,other lesions or circumstances that have reduced the likelihood of entering a group or the complexity of entering a group,such as frequent changes in the working environment, the living environment is not stable,etc.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Comprehensive treatment of TCM
Subjects were treated with comprehensive treatment of TCM including Oral medicine: 1 dose daily by our hospital pharmacy medicine room Decoction decoction, each agent 200ml, and the 2 ton service. 10 days for a course of treatment, continuous treatment of 3 courses; retention enema with traditional Chinese medicine oral drugs according to different types of concentrated decoction enema, each dose of medicine decocting 2 times, 2 days of external application of Chinese medicine: Chinese medicine enema; break into powder, into the bag, steam for 45 minutes, and so the temperature dropped to appropriate, will be installed a Chinese medicine bag used on patients with lower abdomen for 20 minutes. Above method, a course of treatment for 10 days, continuous treatment of 3 courses.
Other:
Expectant treatment
Expectant treatment group patients were not treated during the observation period.(3 months after the start of the trial and 1 months after the end of the trial.)From the point of view of medical ethics, the expectant treatment group of patients at the end of the observation period, given the treatment of traditional Chinese medicine treatment group.

Locations

Country Name City State
China Shanghai Longhua Hosptial Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Shanghai University of Traditional Chinese Medicine

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary changes of The Symptom score Patients are checked The Symptom score at 3 months after treatment. 3 months after treatment No
Secondary changes of The Hamilton Depression Scale (HAMD) (17 items) 1 months after treatment, 2 months after treatment, 3 months after treatment and 1 months after drug withdrawal. No
Secondary changes of The Sign score sheet 1 months after treatment, 2 months after treatment, 3 months after treatment and 1 months after drug withdrawal No
See also
  Status Clinical Trial Phase
Completed NCT04723069 - Efficacy and Safety of Fuke Qianjin Capsule in Patients With Pelvic Inflammatory Diseases Phase 2
Recruiting NCT03391440 - A Trial to Assess the Efficacy and Safety of Morinidazole in Women With Pelvic Inflammatory Disease Phase 4
Completed NCT01671280 - Drug Use Investigation Of Azithromycin IV For Community-Acquired Pneumonia Or Pelvic Inflammatory Disease (Regulatory Post Marketing Commitment Plan) N/A
Completed NCT00115388 - Community-Based Trial of Screening for Chlamydia Trachomatis to Prevent Pelvic Inflammatory Disease N/A
Completed NCT01236131 - The Role of Novel Organisms in Acute Endometritis N/A
Completed NCT01160640 - The Importance of Anti-anaerobic Therapy for Acute Pelvic Inflammatory Disease (PID) Phase 2
Active, not recruiting NCT03994055 - Effect of an Anti-inflammatory Diet on Patients With Cervical Cancer N/A
Completed NCT00871494 - Study Of Azithromycin Intravenous Formulation Against Pelvic Inflammatory Disease (PID) In Japan Phase 3
Completed NCT00783419 - Rate of Pelvic Inflammatory Disease at St. Michael's Hospital
Completed NCT01799356 - Moxifloxacin Versus Ofloxacin Plus Metronidazole in Uncomplicated Pelvic Inflammatory Disease: Multicenter Randomized Controlled Trials Phase 4
Recruiting NCT05408624 - Pilot Study Evaluating Outpatient Management of Tubo-ovarian Abscesses
Completed NCT01241110 - To Compare Ofloxacin With Azitromycin for Pelvic Inflammatory Disease (PID) Treatment Phase 4
Completed NCT00453349 - A Trial Comparing Moxifloxacin Versus Levofloxacin Plus Metronidazole In Uncomplicated Pelvic Inflammatory Disease Phase 3
Recruiting NCT04234945 - Effect of Prophylactic Antibiotics for Hysterosalpingography on Post Procedure Morbidity N/A
Recruiting NCT06360965 - Clinical Trial of Acupoint Application in Improving the Sequelae of Pelvic Inflammatory Disease and Chronic Pelvic Pain N/A
Recruiting NCT05648747 - Pelvic Inflammatory Disease in COVID-19 Era
Completed NCT01793584 - Surgical Success After Laparoscopic vs Abdominal Hysterectomy N/A
Completed NCT01299259 - Improving Primary Care Follow-up for Patients With Pelvic Inflammatory Disease N/A
Completed NCT03054402 - First in Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and to Explore Pharmacodynamics of BAY1834845 Phase 1
Active, not recruiting NCT03828994 - Technology Based Community Health Nursing(TECH-N) to Prevent Recurrent STIs After PID II N/A